<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386761</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-06001AA1-08</org_study_id>
    <nct_id>NCT02386761</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001</brief_title>
  <acronym>CHF6001Ext</acronym>
  <official_title>A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doseS in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I randomised, double-blind, placebo-controlled study of single and repeated ascending&#xD;
      doses in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of&#xD;
      inhaled chf 6001.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of single and repeated ascending doses of CHF 6001 in&#xD;
      healthy volunteers and to investigate the pharmacokinetic (PK) profile of CHF 6001 and its&#xD;
      metabolites CHF 5956 and CHF 6095.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>0-14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg&#xD;
Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg&#xD;
Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.&#xD;
In case the actual doses are modified, the number of inhalations will be adapted accordingly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo&#xD;
Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo&#xD;
Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo&#xD;
Duration 14 days b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Ascending Dose (SAD)</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <other_name>CHF6001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple Ascending Dose (MAD)</intervention_name>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <other_name>CHF6001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion&#xD;
&#xD;
          -  Subject's written informed consent obtained prior to any study-related procedure&#xD;
&#xD;
          -  Male and female Caucasian healthy volunteers aged 18-55 years inclusive&#xD;
&#xD;
          -  Vital signs:Subjects aged 18-45: Diastolic BP 40-90, Systolic BP 90-140 Subjects aged&#xD;
             45-55: Diastolic BP 40-90, Systolic BP 90-150 (as mean of three measures performed&#xD;
             after at least 5 minutes of resting); checked at screening visit and Day -1&#xD;
&#xD;
          -  12-lead digitised Electrocardiogram (12-lead ECG) considered as normal (40≤Heart&#xD;
             rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms&#xD;
             for females) checked at screening visit and Day -1&#xD;
&#xD;
          -  Lung function measurements within normal limits: FEV1 &gt; 80% of predicted normal value&#xD;
             (according to the Global Lung Function Initiative, ERS Task Force Lung Function&#xD;
             Reference Values (1,2) ) and FEV1/FVC ratio &gt; 0.70&#xD;
&#xD;
        Main Exclusion:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Clinically significant cardiac abnormalities&#xD;
&#xD;
          -  Any clinically relevant abnormal laboratory values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>UK</state>
        <zip>NG116JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Jolling K, Äbelö A, Luyckx N, Nandeuil MA, Govoni M, Cella M, Lindauer A. Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation. CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):460-468. doi: 10.1002/psp4.12405. Epub 2019 May 11.</citation>
    <PMID>31077576</PMID>
  </reference>
  <results_reference>
    <citation>Mariotti F, Govoni M, Lucci G, Santoro D, Nandeuil MA. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers. Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3399-3410. doi: 10.2147/COPD.S174156. eCollection 2018.</citation>
    <PMID>30425469</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

